Visium Spatial Proteogenomics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Visium Spatial Proteogenomics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Visium Spatial Proteogenomics Today - Breaking & Trending Today

10x Genomics, Inc. Share Price Target '$58.50', now 21.7% Upside Potential

Published: February 16, 2024

10x Genomics, Inc. Share Price Target '$58.50', now 21.7% Upside Potential

Source: directorstalkinterviews.com

Related Topics:

Genomics IncChromiumx SeriesChromium ConnectChromium ControllerChromium Single Cell Gene ExpressionChromium Single Cell Gene Expression FlexChromium Single Cell Immune ProfilingChromium Single CellChromium Single Cell MultiomeGene ExpressionVisium Spatial Gene ExpressionVisium Spatial ProteogenomicsXenium In Situ Gene

10x Genomics, Inc. - Consensus 'buy' rating and 21.0% Upside Potential

Published: December 7, 2023

10x Genomics, Inc. - Consensus 'buy' rating and 21.0% Upside Potential

Source: directorstalkinterviews.com

Related Topics:

Paylocity Holding CorporationGenomics IncChromiumx SeriesChromium ConnectChromium ControllerChromium Single Cell Gene ExpressionChromium Single Cell Gene Expression FlexChromium Single Cell Immune ProfilingChromium Single CellChromium Single Cell MultiomeGene ExpressionVisium Spatial Gene ExpressionVisium Spatial ProteogenomicsXenium In Situ Gene

10x Genomics, Inc. - Consensus 'buy' rating and 71.0% Upside Potential

Published: November 1, 2023

10x Genomics, Inc. - Consensus 'buy' rating and 71.0% Upside Potential

Source: directorstalkinterviews.com

Related Topics:

Genomics IncChromiumx SeriesChromium ConnectChromium ControllerChromium Single Cell Gene ExpressionChromium Single Cell Gene Expression FlexChromium Single Cell Immune ProfilingChromium Single CellChromium Single Cell MultiomeGene ExpressionVisium Spatial Gene ExpressionVisium Spatial ProteogenomicsXenium In Situ Gene

10x Genomics, Inc. - Consensus 'buy' rating and 12.7% Upside Potential

Published: August 9, 2023

10x Genomics, Inc. - Consensus 'buy' rating and 12.7% Upside Potential

Source: directorstalkinterviews.com

Related Topics:

Genomics IncPaylocity Holding CorporationChromiumx SeriesChromium ConnectChromium ControllerChromium Single Cell Gene ExpressionChromium Single Cell Gene Expression FlexChromium Single Cell Immune ProfilingChromium Single CellChromium Single Cell MultiomeGene ExpressionVisium Spatial Gene ExpressionVisium Spatial ProteogenomicsXenium In Situ Gene